Cargando…
Prognostic and predictive factors in pancreatic cancer
Pancreatic cancer is one of the leading causes of cancer death worldwide. Its high mortality rate has remained unchanged for years. Radiotherapy and surgery are considered standard treatments in early and locally advanced stages. Chemotherapy is the only option for metastatic patients. Two treatment...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075465/ https://www.ncbi.nlm.nih.gov/pubmed/32206189 http://dx.doi.org/10.18632/oncotarget.27518 |
_version_ | 1783507045323898880 |
---|---|
author | Dell’Aquila, Emanuela Fulgenzi, Claudia Angela Maria Minelli, Alessandro Citarella, Fabrizio Stellato, Marco Pantano, Francesco Russano, Marco Cursano, Maria Concetta Napolitano, Andrea Zeppola, Tea Vincenzi, Bruno Tonini, Giuseppe Santini, Daniele |
author_facet | Dell’Aquila, Emanuela Fulgenzi, Claudia Angela Maria Minelli, Alessandro Citarella, Fabrizio Stellato, Marco Pantano, Francesco Russano, Marco Cursano, Maria Concetta Napolitano, Andrea Zeppola, Tea Vincenzi, Bruno Tonini, Giuseppe Santini, Daniele |
author_sort | Dell’Aquila, Emanuela |
collection | PubMed |
description | Pancreatic cancer is one of the leading causes of cancer death worldwide. Its high mortality rate has remained unchanged for years. Radiotherapy and surgery are considered standard treatments in early and locally advanced stages. Chemotherapy is the only option for metastatic patients. Two treatment regimens, i. e. the association of 5-fluorouracil- irinotecan-oxaliplatin (FOLFIRINOX) and the association of nab-paclitaxel with gemcitabine, have been shown to improve outcomes for metastatic pancreatic adenocarcinoma patients. However, there are not standardized predictive biomarkers able to identify patients who benefit most from treatments. CA19-9 is the most studied prognostic biomarker, its predictive role remains unclear. Other clinical, histological and molecular biomarkers are emerging in prognostic and predictive settings. The aim of this review is to provide an overview of prognostic and predictive markers used in clinical practice and to explore the most promising fields of research in terms of treatment selection and tailored therapy in pancreatic cancer. |
format | Online Article Text |
id | pubmed-7075465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-70754652020-03-23 Prognostic and predictive factors in pancreatic cancer Dell’Aquila, Emanuela Fulgenzi, Claudia Angela Maria Minelli, Alessandro Citarella, Fabrizio Stellato, Marco Pantano, Francesco Russano, Marco Cursano, Maria Concetta Napolitano, Andrea Zeppola, Tea Vincenzi, Bruno Tonini, Giuseppe Santini, Daniele Oncotarget Review Pancreatic cancer is one of the leading causes of cancer death worldwide. Its high mortality rate has remained unchanged for years. Radiotherapy and surgery are considered standard treatments in early and locally advanced stages. Chemotherapy is the only option for metastatic patients. Two treatment regimens, i. e. the association of 5-fluorouracil- irinotecan-oxaliplatin (FOLFIRINOX) and the association of nab-paclitaxel with gemcitabine, have been shown to improve outcomes for metastatic pancreatic adenocarcinoma patients. However, there are not standardized predictive biomarkers able to identify patients who benefit most from treatments. CA19-9 is the most studied prognostic biomarker, its predictive role remains unclear. Other clinical, histological and molecular biomarkers are emerging in prognostic and predictive settings. The aim of this review is to provide an overview of prognostic and predictive markers used in clinical practice and to explore the most promising fields of research in terms of treatment selection and tailored therapy in pancreatic cancer. Impact Journals LLC 2020-03-10 /pmc/articles/PMC7075465/ /pubmed/32206189 http://dx.doi.org/10.18632/oncotarget.27518 Text en Copyright: © 2020 Dell’Aquila et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Dell’Aquila, Emanuela Fulgenzi, Claudia Angela Maria Minelli, Alessandro Citarella, Fabrizio Stellato, Marco Pantano, Francesco Russano, Marco Cursano, Maria Concetta Napolitano, Andrea Zeppola, Tea Vincenzi, Bruno Tonini, Giuseppe Santini, Daniele Prognostic and predictive factors in pancreatic cancer |
title | Prognostic and predictive factors in pancreatic cancer |
title_full | Prognostic and predictive factors in pancreatic cancer |
title_fullStr | Prognostic and predictive factors in pancreatic cancer |
title_full_unstemmed | Prognostic and predictive factors in pancreatic cancer |
title_short | Prognostic and predictive factors in pancreatic cancer |
title_sort | prognostic and predictive factors in pancreatic cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075465/ https://www.ncbi.nlm.nih.gov/pubmed/32206189 http://dx.doi.org/10.18632/oncotarget.27518 |
work_keys_str_mv | AT dellaquilaemanuela prognosticandpredictivefactorsinpancreaticcancer AT fulgenziclaudiaangelamaria prognosticandpredictivefactorsinpancreaticcancer AT minellialessandro prognosticandpredictivefactorsinpancreaticcancer AT citarellafabrizio prognosticandpredictivefactorsinpancreaticcancer AT stellatomarco prognosticandpredictivefactorsinpancreaticcancer AT pantanofrancesco prognosticandpredictivefactorsinpancreaticcancer AT russanomarco prognosticandpredictivefactorsinpancreaticcancer AT cursanomariaconcetta prognosticandpredictivefactorsinpancreaticcancer AT napolitanoandrea prognosticandpredictivefactorsinpancreaticcancer AT zeppolatea prognosticandpredictivefactorsinpancreaticcancer AT vincenzibruno prognosticandpredictivefactorsinpancreaticcancer AT toninigiuseppe prognosticandpredictivefactorsinpancreaticcancer AT santinidaniele prognosticandpredictivefactorsinpancreaticcancer |